

Thomas Aagaard Rasmussen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/169376/publications.pdf>

Version: 2024-02-01

59
papers

3,137
citations

236912

25
h-index

161844

54
g-index

60
all docs

60
docs citations

60
times ranked

3272
citing authors

#	ARTICLE	IF	CITATIONS
1	Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. <i>Lancet HIV</i> , 2014, 1, e13-e21.	4.7	542
2	The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. <i>PLoS Pathogens</i> , 2015, 11, e1005142.	4.7	445
3	Comparison of HDAC inhibitors in clinical development. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 993-1001.	3.3	173
4	Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. <i>Lancet HIV</i> , 2016, 3, e463-e472.	4.7	159
5	Shocking HIV out of hiding. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 394-401.	3.8	130
6	Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2017, 64, 1686-1695.	5.8	122
7	A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4 ⁺ T Cells. <i>Journal of Virology</i> , 2016, 90, 4441-4453.	3.4	94
8	Histone Deacetylase Inhibitors for Purging HIV-1 from the Latent Reservoir. <i>Molecular Medicine</i> , 2011, 17, 466-472.	4.4	93
9	HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission. <i>PLoS Pathogens</i> , 2015, 11, e1005000.	4.7	92
10	Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat. <i>Journal of Virology</i> , 2015, 89, 10176-10189.	3.4	89
11	Reversal of Latency as Part of a Cure for HIV-1. <i>Trends in Microbiology</i> , 2016, 24, 90-97.	7.7	88
12	Broad activation of latent HIV-1 in vivo. <i>Nature Communications</i> , 2016, 7, 12731.	12.8	65
13	HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. <i>JCI Insight</i> , 2017, 2, .	5.0	59
14	Comparison of Bone and Renal Effects In HIV-infected Adults Switching to Abacavir or Tenofovir Based Therapy in a Randomized Trial. <i>PLoS ONE</i> , 2012, 7, e32445.	2.5	53
15	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. <i>Science Translational Medicine</i> , 2022, 14, eabl3836.	12.4	50
16	Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients. <i>PLoS ONE</i> , 2013, 8, e62074.	2.5	49
17	Between a shock and a hard place: challenges and developments in HIV latency reversal. <i>Current Opinion in Virology</i> , 2019, 38, 1-9.	5.4	47
18	Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 790-799.	3.3	44

#	ARTICLE	IF	CITATIONS
19	Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv037.	0.9	42
20	The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. <i>Lancet HIV</i> , 2018, 5, e221-e230.	4.7	34
21	Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e1973-e1981.	5.8	34
22	Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir. <i>Molecular Medicine</i> , 2015, 21, 337-345.	4.4	32
23	Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 328-337.	2.1	32
24	Patient-reported outcomes in daily clinical practise in HIV outpatient care. <i>International Journal of Infectious Diseases</i> , 2018, 69, 108-114.	3.3	31
25	Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations. <i>Aids</i> , 2017, 31, 771-779.	2.2	29
26	Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. <i>Aids</i> , 2010, 24, 1315-1322.	2.2	26
27	Histone Deacetylase Inhibitor Romidepsin Inhibits De Novo HIV-1 Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3984-3994.	3.2	26
28	Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. <i>BMJ</i> , 2012, 345, e5823-e5823.	6.0	25
29	Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy. <i>BMC Infectious Diseases</i> , 2011, 11, 267.	2.9	24
30	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. <i>EBioMedicine</i> , 2021, 65, 103241.	6.1	24
31	Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. <i>Journal of Virology</i> , 2017, 91, .	3.4	21
32	In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. <i>Aids</i> , 2019, 33, 605-613.	2.2	21
33	Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days. <i>PLoS Pathogens</i> , 2016, 12, e1005740.	4.7	21
34	The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients. <i>Aids</i> , 2015, 29, 1195-1200.	2.2	20
35	Ethics of ART interruption after stem-cell transplantation. <i>Lancet HIV</i> , 2016, 3, e8-e10.	4.7	20
36	HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. <i>Aids</i> , 2016, 30, 713-721.	2.2	19

#	ARTICLE	IF	CITATIONS
37	Cancer therapies in HIV cure research. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 96-104.	3.8	19
38	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. <i>Cell Reports</i> , 2020, 33, 108502.	6.4	19
39	Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits <i>Ex Vivo</i> Lipopolysaccharide-Induced Inflammatory Responses. <i>MSphere</i> , 2018, 3, .	2.9	17
40	Clinical Interventions in HIV Cure Research. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 285-318.	1.6	16
41	The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. <i>Aids</i> , 2021, 35, 1631-1636.	2.2	16
42	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells <i>Ex Vivo</i> in People Living with HIV on Antiretroviral Therapy. <i>Journal of Immunology</i> , 2022, 208, 54-62.	0.8	16
43	Immune checkpoint blockade in HIV. <i>EBioMedicine</i> , 2022, 76, 103840.	6.1	15
44	Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. <i>Journal of Virology</i> , 2017, 91, .	3.4	14
45	Kick and kill for HIV latency. <i>Lancet, The</i> , 2020, 395, 844-846.	13.7	14
46	Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency <i>ex vivo</i> without T cell activation. <i>Journal of Virus Eradication</i> , 2019, 5, 133-137.	0.5	13
47	Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency. <i>Journal of Virology</i> , 2018, 92, .	3.4	12
48	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. <i>EBioMedicine</i> , 2021, 65, 103252.	6.1	12
49	Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients. <i>Mediators of Inflammation</i> , 2015, 2015, 1-11.	3.0	10
50	The potential role for romidepsin as a component in early HIV-1 curative efforts. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 447-450.	4.4	10
51	Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. <i>Aids</i> , 2017, 31, 1839-1845.	2.2	10
52	Modeling of Antilateness Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?. <i>Journal of Virology</i> , 2017, 91, .	3.4	10
53	No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2017, 31, 1137-1141.	2.2	9
54	Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. <i>Aids</i> , 2022, 36, 75-82.	2.2	7

#	ARTICLE	IF	CITATIONS
55	Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral rebound. <i>Aids</i> , 2021, 35, 2269-2279.	2.2	6
56	Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency without T cell activation. <i>Journal of Virus Eradication</i> , 2019, 5, 133-137.	0.5	6
57	Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design. <i>Journal of Infectious Diseases</i> , 2022, 226, 236-245.	4.0	2
58	Toll-like Receptor 7 Agonists in People Living With HIV: Implications for Immunotherapeutic Strategies for an HIV Cure. <i>Clinical Infectious Diseases</i> , 2021, 72, e825-e827.	5.8	0
59	Factors associated with weak positive SARS-CoV-2 diagnosis by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR). <i>Pathology</i> , 2022, , .	0.6	0